Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women


About this study

This is a pilot study to evaluate whether targeting inflammation will help reduce markers of insulin resistance inflammation, bone resorption and physical dysfunction in elderly women with gait disturbance. Positive results of this study would lead to the development of a larger clinical trial examining the effects of this intervention on age-related dysfunction.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Healthy postmenopausal women.
  • Age ≥ 70 years old.

Exclusion Criteria

  • Abnormality in any of the screening laboratory studies.
  • Presence of significant liver or renal disease.
  • Malignancy (including myeloma).
  • Malabsorption.
  • Hypoparathyroidism.
  • Hyperparathyroidism.
  • Acromegaly.
  • Cushing’s syndrome.
  • Hypopituitarism.
  • Gastric bypass/reduction.
  • Malabsorption issues.
  • Crohn's.
  • Myopathies (increased or low calcium, vitamin D deficiency, elevated creatine kinase or ESR).
  • If diabetic AND on sulfonylureas (like glipizide, glimepiride, glyburide), SGLT2 inhibitors (like dapagliflozin and empagliflozin), or insulin.
  • Undergoing treatment with any medications that affect bone turnover, including the following:
    • adrenocorticosteroids (> 3 months at any time or > 10 days within the previous year), anticonvulsant therapy (within the previous year);
    • pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal);
    • calcium supplementation of > 1200 mg/d (within the preceding 3 months);
    • bisphosphonates (within the past 3 years);
    • denosumab;
    • estrogen (E) therapy or treatment with a selective E receptor modulator, or teriparatide (within the past year).
  • Subjects with a fracture within the past year.
  • Subjects taking potentially senolytic agents within the last year: Fisetin, Quercetin, Luteolin, Dasatinib, Piperlongumine, or Navitoclax.
  • Subjects currently taking drugs that induce cellular senescence: alkylating agents, anthracyclines, platins, other chemotherapy.
  • Inability to provide informed consent.
  • Total bilirubin > 2X upper limit.
  • Inability to tolerate oral medication.
  • eGFR < 15 ml/ min/ 1.73 m^2.
  • Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.).
  • Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin.
  • Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy prior to and during the 2-day Fisetin dosing.
  • Subjects taking the following other drugs if they cannot be held for at least 2 days before and during administration of Fisetin: digoxin, lithium, all statins, repaglidine, bosentan, gemfibrozil, olmesartan, enalapril, valsartan, methotrexate, corticosteroids, thyroid hormones, eluxadoline, eltrombopag, nitroglycerin, pioglitazone, glyburide, enzalutamide, ezetimibe, colchicine, imatinib, cyclosporine, tacolimus, sirolimus, carbamazepine, flecainide, phenytoin, phenobarbital, rifampicin, theophylline, warfarin, heparin, full dose ASA, clopidogrel, celecoxib, desipramine, thioridazine, venlafaxine, tizanidine, atomoxetine, voriconazole, citalopram, diazepam, escitalopram, propranolol, clozapine, cyclobenzaprine, mexiletine, olanzapine, ondansetron, riluzole.
  • In order to ensure vitamin D sufficiency, we will also exclude subjects with serum 25-hydroxyvitamin D levels of < 20 ng/ml.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

James Kirkland, M.D., Ph.D.

Contact us for the latest status

Contact information:

Tamara Evans

(507) 284-1004

More information


Publications are currently not available

Mayo Clinic Footer